Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART20.1 in Metastatic Melanoma
NCT03893019Phase 1Terminated
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Mar 2019
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MB-CART20.1 in melanoma (3 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Safety and Toxicity Assessment at 28 days. Started Mar 2019; status: terminated.
02
Drugs
MB-CART20.1
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03893019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893019.